PFE

Pfizer to Share Revenue With HHS in Deal on Overseas Drug Prices

The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents.

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree

Pfizer (PFE), What Is Drawing Fresh Attention Now?

Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of n

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index adding 0.8% and the S

Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears

On September 3, Vaxcyte (NASDAQ:PCVX) announced two new C-suite hires and moved up the date for its most important looming catalyst. The company said it now expects topline safety, tolerability and immunogenicity data fr

All 50 States Joining Medicaid Drug Pricing Model After Pharma Deals, Trump Says

Drug companies had incentives to participate in the deals to stave off the threat of U.S. tariffs on their products.

What Would It Take For Eli Lilly Stock To Keep Climbing?

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Fou

Merck Stock Nearly Doubled Without A Change In Its Revenue Growth

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investor